Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 1/20 | 0.38 |
| ▸ | DRD3 | P35462 | 1/20 | 0.38 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.38 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.37 |
| ▸ | CA2 | P00918 | 1/20 | 0.34 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.34 |
| ▸ | PYGL | P06737 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | BLM | P54132 | 1/20 | 0.33 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.32 |
| ▸ | PPARG | P37231 | 1/20 | 0.32 |
| ▸ | PPARD | Q03181 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13895525 | 0.82 | DRD2 (0.38) | DRD2DRD3HCRTR2CYP19A1CA2 | |
| SCHEMBL12355153 | 0.76 | DRD2 (0.40) | DRD2DRD3HCRTR2CYP19A1CA2 | |
| SCHEMBL16693108 | 0.71 | DRD2 (0.41) | DRD2DRD3HCRTR2CYP19A1CA2 | |
| SCHEMBL29222597 | 0.69 | ADRA2A (0.47) | DRD2DRD3HCRTR2CYP19A1ADRA2A | |
| SCHEMBL29340304 | 0.68 | DRD2 (0.43) | DRD2DRD3HCRTR2CYP19A1CA2 | |
| SCHEMBL22439161 | 0.68 | DRD2 (0.43) | DRD2DRD3HCRTR2CYP19A1CA2 | |
| SCHEMBL31603066 | 0.68 | DRD2 (0.43) | DRD2DRD3HCRTR2CYP19A1CA2 | |
| SCHEMBL30015979 | 0.68 | DRD2 (0.43) | DRD2DRD3HCRTR2CYP19A1CA2 | |
| SCHEMBL31603070 | 0.68 | DRD2 (0.43) | DRD2DRD3HCRTR2CYP19A1CA2 | |
| SCHEMBL31136565 | 0.68 | DRD2 (0.43) | DRD2DRD3HCRTR2CYP19A1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110190247-A1 | CYCLOPROPYLCHROMENE DERIVATIVES AS MODULATORS OF THE ALPHA-2C RECEPTOR | SCHERING CORPORATION (US) | 2011-08-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110190247-A1 | CYCLOPROPYLCHROMENE DERIVATIVES AS MODULATORS OF THE ALPHA-2C RECEPTOR | ADRA2C, ADRB2, ADRA2A | DRD2 211/4885DRD3 307/4885HCRTR2 68/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.